Happyglip M 500mg/50mg Tablet is a fixed-dose combination medication containing Metformin 500mg and Vildagliptin 50mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby effectively lowering blood glucose levels. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by preventing the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), resulting in increased insulin secretion and decreased glucagon release in a glucose-dependent manner. The combination of these two agents offers complementary mechanisms of action, improving glycemic control more effectively than either agent alone. Happyglip M is typically prescribed when monotherapy with Metformin is insufficient to achieve target glycemic levels. It is important to use this medication alongside diet and exercise for optimal diabetes management. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while hypoglycemia risk is generally low but may increase when combined with other antidiabetic agents. Caution is advised in patients with renal impairment, hepatic dysfunction, or heart failure. Regular monitoring of blood glucose and renal function is recommended during therapy.